Introduction
The complications and costs of diabetes rise exponentially as hemoglobin A1c (HbA1c) increases. [1] [2] [3] Because HbA1c reduction prevents diabetes complications, 1,4 patients with persistent poorly controlled diabetes mellitus (PPDM), or maintenance of an HbA1c .9% for .1 year, despite clinic-based care, 5 contribute disproportionately to the nationwide diabetes burden. 6, 7 The prevalence of PPDM is ~10% of US adults with diabetes. 6, 8, 9 Clinic-based care is suboptimal for PPDM patients because the infrequent patientprovider contact achievable in the outpatient setting may not support patients in accommodating the complex self-management demands PPDM requires. 8, 10, 11 The burden imposed by PPDM is substantial; PPDM patients are expected to check their blood sugar several times daily, administer multiple daily insulin injections, modify their diet, and exercise regularly. Concurrently, patients with PPDM often experience challenges that affect their capacity to manage this burden of demands; these challenges may include aversion to needles, 12 comorbid conditions with complex treatment regimens, 8, 12 suboptimal patient-provider relationships, 13 and deficits in knowledge, skills, motivation, social support, and self-efficacy. [12] [13] [14] [15] [16] Patients with PPDM also face barriers unrelated to their disease that could impact their capacity to self-manage, such as work and family responsibilities. In the absence of additional supports to overcome these barriers, patients may be unable or unwilling to fully engage with diabetes self-management. 17, 18 Telemedicine is the remote delivery of health care services and clinical information using telecommunications technology. 19 It is a modality for providing additional support to PPDM patients beyond what is feasible in the clinic setting. Specifically, telephone-delivered care can minimize treatment burden by eliminating some clinic appointments in favor of a more convenient mechanism. Studies have shown that provider review of self-monitored blood glucose (SMBG) data, self-management support, and medication management, all strategies that address specific factors contributing to poor diabetes control, can be adapted to the telemedicine setting and may even be enhanced by use of telemedicine. [20] [21] [22] [23] [24] [25] Telemonitoring, in which patients transmit SMBG values to providers via telephone, increases providers' access to data that can inform treatment recommendations. 26 Both self-management support and medication management rely on regular, supportive interactions between patients and providers, 10, 11, 21, [26] [27] [28] which can be achieved more frequently and at lesser burden to patients when carried out via phone. Thus, a comprehensive telemedicine intervention combining telemonitoring, selfmanagement support, and medication management could address multiple factors underlying poor control and improve outcomes in the high-risk PPDM population.
However, few health care systems have implemented comprehensive telemedicine interventions for PPDM in clinical practice, potentially due to the fact that such interventions have seldom been designed for delivery under real-world conditions. 29, 30 If an intervention combining telemonitoring, self-management support, and medication management could be delivered using the target organization's existing staffing and infrastructure, it may be well suited to address the complex needs of patients with PPDM in practice.
Advanced Comprehensive Diabetes Care (ACDC) is a comprehensive telemedicine intervention for PPDM that was developed to 1) meet the complex management needs of patients with PPDM and 2) leverage existing telemedicine infrastructure within the Veterans Affairs (VA) health system. ACDC, which is designed for delivery by VA home telehealth (HT) nurses during biweekly telephone encounters, combines telemonitoring, self-management support, and medication management. While these intervention components have been individually found to improve glycemic control, bundling them into a comprehensive telemedicine intervention designed for practical delivery via existing infrastructure represents a novel approach. We piloted ACDC within the Durham VA during 2013-2014 and found that it improved HbA1c by an average of 1% relative to usual care at 6 months. 5 Patients completing at least half of the scheduled telephone encounters achieved a mean HbA1c reduction of ~2%.
5
To inform refinement and expansion of the ACDC approach, we qualitatively evaluated how, and for whom, ACDC worked to improve diabetes control. We conducted and analyzed semistructured interviews with participants to elicit their experiences with ACDC. We organized participant responses according to their clinical outcomes, specifically noting differences between participants with highest and lowest HbA1c change (,1% vs $1%). We also conducted interviews with the two VA HT nurses who delivered ACDC, to triangulate their accounts with those of participants.
Methods
Details of the ACDC randomized trial (NCT01778751) are described elsewhere. 5 This study was approved by the Durham VA Medical Center Institutional Review Board. Briefly, ACDC was a 6-month telemedicine intervention (N=50) in which Durham VA HT nurses working with our research team delivered intervention content to study participants via biweekly calls. Participants were instructed to monitor their blood glucose three to four times per day and self-report their values daily using standard Durham VA telemedicine equipment (Cardiocom; TeleResponse Interactive Voice Response System, Chanhassen, MN, USA). During each call, HT nurses and participants reviewed interim blood glucose data, reconciled medications, and assessed medication adherence; at most encounters, nurses delivered self-management support modules on topics such as managing hypoglycemia. Following each encounter, a study physician reviewed patients' blood glucose data and recommended medication changes as indicated, and HT nurses implemented these recommendations.
At the end of the 6-month pilot, semistructured interviews were conducted with 18 out of 23 participants who completed the intervention arm of the randomized trial, and with the 
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Patient perceptions of a comprehensive telemedicine intervention 2 HT nurses who delivered ACDC; these participants all provided written informed consent for their data to be used in the study, as well as verbal consent for their interviews to be audiorecorded. Five out of 23 participants declined to be interviewed (n=4) or were lost to follow-up (n=1) at the time that interviews were conducted. Interview questions probed about how intervention components impacted participants and about barriers to engagement with the intervention (Tables 1 and 2 ). All interviews were transcribed and analyzed using directed content analysis. 31 Specifically, codes (ie, descriptive labels assigned to text) were designated a priori based on questions about intervention components (eg, "self-monitoring blood glucose"). During initial coding, additional data-derived codes were developed to represent participant characteristics (eg, "handling competing demands") and their perspectives about the intervention's value (eg, "becoming more mindful"). Two experienced health services researchers (NRS and JMG) and a content expert (MJC) coded half of the transcripts individually and then reviewed as a group to achieve consensus through discussion and deliberation. 32 Codes were refined by another researcher (SMA) using constant comparison technique, in what ways was it not helpful?
ACDC home telehealth nurse interaction:
The telehealth nurse called you at least once every other week to discuss your blood sugars, which we asked you to check at home and send into the VA by telephone.
• What did you think about these calls? Were they helpful or not?
• how did you feel about the frequency of these calls? Were they too often? not often enough?
• how did you feel about how long these calls took? Were they too long? Too short? Blood glucose self-monitoring: now let us talk a bit about home blood sugar monitoring.
• What was it like for you to measure your blood sugar at home?
• Was there anything difficult about measuring your blood sugars? If so, what?
• Tell me about any changes you have made as the result of measuring your blood sugar at home. how did it affect your diet? how did it affect your exercise habits? how did it affect the way you take your medications? What other ways did checking your blood sugar levels at home influence your life? • in the future, how likely would you be to continue monitoring and transmitting blood sugar readings from home if you had the chance? Tell me more about that.
• What would make it easier for you to check and transmit your home blood sugar readings?
• How does at-home blood sugar reading fit with your regular VA care? Do you feel that transmitting your home blood sugar readings replaced some of your clinic visits or do you feel that this is an additional piece of your VA care? Tell me more about that.
ACDC diabetes medication management intervention:
The telehealth nurse also called you to give you information about changes to your diabetes medications recommended by our study doctor.
• how did you feel about having your insulin or other medication adjusted by phone?
• how did this affect the way you take your insulin and other medications?
• What did you do with the recommendations? Did you accept them or not? Tell me more.
• how has this affected your relationship with your primary provider? ACDC self-care behavior support intervention: The telehealth nurse also reviewed with you lots of information about how to best take care of your diabetes.
• What do you think about the information the nurse shared with you? Did you find it helpful or not? In what ways?
• how did this information affect the way you monitor your sugar, take your insulin, and follow recommendations about diet and exercise?
• how has this affected your relationship with your primary provider? Closing questions:
• if we could do anything to change the program we offered you to make it better meet your needs, what would that be?
• is there anything that you would like to mention that i did not ask about? At least once every other week, you spoke with intervention patients by phone to discuss their blood sugars and evaluate medication adherence.
• how receptive were patients to the idea of monitoring their blood sugars and reporting them by phone? can you tell me more about this?
• how did you feel about how long these calls took? Were they too long? Too short?
• What worked well about your interactions with patients with respect to blood sugar monitoring? What did not work well?
• how did patients respond to the recommended blood sugar monitoring? Were they generally adherent or not? Tell me more.
• What do you think are the biggest barriers to adherence to the recommended blood sugar monitoring in this study?
• how was it to assess patients' adherence to their medications during these calls? Do you think that you were able to do this accurately?
Tell me more.
• What would you change or improve about the AcDc intervention with respect to blood sugar monitoring and medication adherence evaluation? ACDC diabetes medication management: At times, you were asked to relay recommendations regarding diabetes medication adjustments from the study physician to patients.
• how receptive were patients to having their diabetes medications adjusted by phone? Did patients accept the recommendations?
• how long did the process of relaying medication adjustment recommendations take? how could this process be improved?
• What kinds of questions did patients have? how was it for you to answer these?
• how did patients feel about how phone-based medication adjustment might affect their relationship with their primary provider?
• What would you change or improve about the AcDc intervention with respect to the process of diabetes medication adjustment? ACDC self-care behavior support: You also reviewed information with patients regarding diabetes self-care support.
• how receptive were patients to information regarding diabetes self-care by phone? Did patients accept the recommendations?
• how long did the process of relaying information regarding diabetes self-care take? Was this too long?
• What conversations did you have with patients about how this part of the intervention might affect their relationship with their primary provider?
Did they seem concerned? Tell me more.
• What would you change or improve about the AcDc intervention with respect to the process of diabetes self-care support? Provider interaction:
• in general, what was it like to interact with the study physician and study psychiatrist?
how did the process whereby you conveyed data to the study providers and received recommendations for medication changes work? how available were the study providers for dialog with you when necessary? Did you have questions about the rationale behind providers' recommendations? Or did you understand the rationale? Tell me more. Did you generally agree with the recommendations? Tell me more.
• how did these interactions generally take place?
Was there one modality (phone, email, etc) that you used most commonly? Was there one that worked the best? • What would you change or improve about the AcDc intervention with respect to the process of interacting with study providers? Closing questions:
• if we could do anything else to change the AcDc intervention to make it work better, what would that be?
• is there anything that you would like to mention that i did not ask about?
Abbreviation: AcDc, Advanced comprehensive Diabetes care.
an iterative process of comparing and recoding text as code properties are developed. 33, 34 The final codes were applied to all transcripts (Table 3) . Coded data were then organized in a matrix to identify themes about how participants with similar characteristics and/or outcomes valued program components. Rows represented outcomes of HbA1c change (,1% or $1%), and columns represented categories of coded data: patient characteristics and program structure.
Results

sample characteristics
Interview participants were 18 men (mean age =60) who completed ACDC, and the 2 ACDC telehealth nurses, both female. According to inclusion criteria for the ACDC pilot, all participants were identified as having PPDM, defined as HbA1c of .9% for .1 year, despite receiving standard clinic-based care. classified as "low-change" because their HbA1c improved by ,1% and n=14 were classified as "high-change" because their HbA1c improved by $1. Among low-change participants, n=2 completed 3 out of 12 possible encounters with HT nurses, and n=2 completed $6 out of 12 possible encounters with HT nurses. Among high-change participants, most (n=13) completed $6 out of 12 possible encounters.
Findings
We present aspects of the intervention experience that were common across participants and results for each category of HbA1c change (,1% and $1%), using data from both participant and nurse interviews.
regardless of hbA1c change, participants reported increased awareness of their diabetes and frustration with the telemonitoring interface Self-monitoring more frequently as a result of intervention components led most participants (n=15) to become aware of fluctuations in their blood glucose. Some (n=4) said they were able to monitor their blood glucose more frequently because study nurses arranged for them to receive selfmonitoring supplies. Participants (n=10) also described how HT nurse encounters and telemonitoring provided accountability and increased their motivation for self-monitoring. Nurses also described how they motivated participants: "Some of it is just reinforcing what they already know and encouraging them to take ownership of it."
Another common theme among all participants was the burden imposed by the telemonitoring reporting interface. While daily the telemonitoring component of the intervention provided accountability for their SMBG, many (n=10) indicated that the reporting interface did not fit easily into their daily routines. The VA's telemonitoring system is programmed to deliver follow-up questions and recommendations, based on reported blood glucose values, to all telehealth patients. Participants were frustrated that the length of the telemonitoring calls was extended by computerized recommendations, which they described as repetitive and redundant, and by having to repeat entries when the computer did not correctly record their values. Other participants (n=5) desired more flexibility, for example, to be able to enter .1 day's readings at a time rather than telemonitoring daily, or, for those whose work environments did not accommodate regular use of their phones, the ability to report via an alternate device. 
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Andrews et al When I travel out of the country and I was not able to call in for a couple of weeks, the data was not available. It would be nice if there was a way to do it electronically that would complement the phone service.
For some, the inconvenience and/or stress of using the interface reduced their willingness to engage with the intervention. For example, when describing his attempts to report his blood glucose values, one said: When asked if they would be willing to continue telemonitoring their blood glucose, participants (n=5) said that they would not be willing if it meant continuing to report their blood glucose through the same telemonitoring system, although most qualified that they would be willing if there were changes to the system (eg, omission of automated recommendations).
Participants whose hbA1c improved by ,1% described competing demands that limited their engagement with the intervention While most low-change participants reported overall satisfaction with the intervention, all (n=4) reported barriers in their lives that affected their capacity to address their diabetes and engage fully with intervention components. Low-change participants (n=3) described health issues such as comorbid illnesses, physical injuries, and medication side effects, which affected their ability or willingness to accept selfmanagement recommendations (eg, to exercise) and adhere to medication adjustments. For example, one participant did not take the medication prescribed by the study physician because he said that they made him feel sick. Another described shoulder pain that prevented him from working for 3 months, with resultant high blood glucose values that he attributed to stress. And one described how "depression" hindered his self-monitoring, saying, Sometimes I got the grit that I can do it, and a couple of days or later on that afternoon I may be in a different mood
[…] and I do not give a damn.
Low-change participants (n=3) also said that their daily commitments, including work and family obligations, did not accommodate intervention components. When referring to the telemonitoring process, one participant said:
That [telemonitoring interface] would keep you on the phone for fifteen to twenty minutes. I have not got that time.
I got three kids, a wife, and we are a very busy family. Plus I work twelve hour shifts at work.
Another said that his irregular schedule made it difficult to perform important self-care activities such as eating and taking medications at specific times; he also said that he frequently forgot to bring his mobile phone with him during the day, rendering him unable to participate in telemonitoring.
Nurse feedback echoed comments by some low-change participants about their difficulty participating in intervention components. One nurse said:
I had one patient […] who actually works two jobs and he is gone from like 7-3 and 3-midnight. I mean, there was almost no time that you could ever call this man. I think I got him on the phone twice.
She also reported seeing a correlation between participation in nurse HT encounters and participation in the telemonitoring component of the intervention, saying: "The same ones that we struggled trying to contact, they also struggled with reporting."
Participants whose hbA1c improved by $1% described how participation in the intervention bolstered their capacity to manage their diabetes Some high-change participants (n=9) reported similar challenges to participation as low-change participants, including comorbid injury and illness, work schedules that conflicted with telemonitoring, and family responsibilities. Despite these challenges, high-change participants reported that they engaged with intervention components and described how the intervention supported them in ways that bolstered their capacity to self-manage.
Participants (n=8) who achieved the highest HbA1c change described improved diabetes control when the study physician made multiple adjustments to their medications and they adhered to these adjustments. Some (n=3) appreciated that the study physician accommodated their medication preferences, such as wanting to avoid injectable insulin, and attributed improved adherence to finding their medication regimens tolerable. For example, one said: High-change participants (n=7) also described how personalized education from the HT nurses about their diet and medications helped them establish new routines that led to better diabetes control. One said:
The biggest help was educating more about what to eat, and when to take my pills. Because you know I was taking my pills randomly […] it helped me to know that you are supposed to take a pill, then after you take a pill, you eat 30 minutes after you take the pill.
Participants (n=4) also described how they developed new eating habits after their HT nurse arranged individualized nutrition counseling with a dietitian. Nurses echoed the importance of personalized education in forming new selfmanagement routines and attributed participants' positive outcomes to more frequent encounters. One said, Nurses stated that the frequency of their contact with ACDC participants allowed them to form a relationship that differed from their typical telehealth nursing encounters, which only occurred when a patient's reported values were dangerously high or low.
High-change participants (n=6) described that their motivation to manage their diabetes increased as they received support from intervention components. For example, one described how the HT nurse helped him prioritize his diabetes self-care:
When I first started the program I was a caretaker for my Others (n=5) said that they were motivated to improve their diabetes control prior to starting the intervention and thus were more receptive to intervention components. For example, one said: "Well, I was just kind of feeling like crap all the time […] So, I was looking for a change and I was ready for a change."
Discussion
The ACDC intervention was designed to comprehensively address factors contributing to PPDM by combining telemonitoring, self-management support, and medication management. Critically, ACDC sought to leverage existing VA telemedicine infrastructure to promote practical intervention delivery and potentially facilitate eventual implementation. Feedback from participants generally indicated that this combination of strategies supported them in improving HbA1c through enhanced awareness of blood glucose fluctuation, provision of support for developing self-management routines, and frequent medication management, even though there was widespread frustration with the telemedicine interface. Differences were noted between participants with higher versus lower HbA1c improvement, in that participants with ,1% improvement reported that competing demands interfered with their engagement, and participants with $1% improvement reported increased capacity to self-manage as a result of engaging with the intervention.
Prior studies have elucidated mechanisms by which the three ACDC intervention components are effective: telemonitoring has been described as a cue to action and source of accountability for SMBG that leads to increased awareness of diabetes control; 20, 23, 26, 35 self-management support has been described as a source of accountability and social support; 21, 25, 28, 36 and more frequent medication management has been shown to improve clinical outcomes and patientprovider relationships. 24, 27, [37] [38] [39] ACDC participants' description of their interactions with intervention components supported these proposed mechanisms of effectiveness. ACDC builds on existing knowledge through two innovations: the comprehensive nature of the intervention and the use of existing telemedicine infrastructure to deliver the intervention.
Treating a complex disease with a comprehensive intervention
By focusing on PPDM, we deliberately sought out the highest risk diabetes patients in VA and targeted them with an intensive, comprehensive telemedicine intervention. Because patients with PPDM contribute disproportionately to the nationwide diabetes burden, 6, 7 addressing PPDM with a high-intensity intervention like ACDC may represent an appropriate matching of resources to clinical need. Our 
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Andrews et al results suggest that it may be the combination of intervention strategies, rather than individual strategies, which had the greatest effect on outcomes. High-change participants indicated that telemonitoring and HT nurse encounters prompted them to self-monitor more frequently, which increased their awareness of blood glucose fluctuations. Participants also received regular medication management based on the blood glucose values they reported. As they accepted medication adjustments and made lifestyle changes in response to SMBG, it is possible that patients' improved diabetes control enhanced their motivation for self-management, leading to further positive behavior change. Thus, intervention components may have interacted to initiate a positive feedback loop wherein participants' engagement with the intervention led to positive clinical outcomes and rendered them better able and more motivated to sustain changes. 17 capitalizing on existing infrastructure to facilitate practical delivery
To foster comprehensive telemedicine-based management as a much-needed alternative to insufficiently effective clinicbased care for PPDM, we designed ACDC for practical delivery using existing VA infrastructure. There is a clear clinical need for alternative approaches when patients do not respond to clinic-based measures; but to our knowledge, neither VA nor any other system has addressed this need in practice. By leveraging VA's investment in telemedicine, ACDC has potential for eventual widespread implementation and thus ample promise to widely impact Veterans with PPDM.
Of note, we found that our use of existing VA telemonitoring infrastructure was a source of frustration for many patients. The use of telemedicine modalities is intended to alleviate treatment burden, but telemonitoring interfaces have been cited as barriers to participation and impediments to satisfaction in many telemedicine studies. 24, 26, 35, 36 This is problematic, because the fit of telemedicine innovations into patients' lives is critical to the success and sustainability of interventions that employ them. 26 In ACDC, the limitations of the VA's telemonitoring interface burdened some participants to the point of impeding participation.
Future work should focus on optimizing telemonitoring infrastructure to minimize burden on participants, thus facilitating engagement in self-management activities. However, the potential advantages of innovative telemonitoring technology that is more user-friendly, but less widely available, must be weighed against the potential for widespread implementation. 28, 29 Despite frustration with the VA's existing telemonitoring interface, most ACDC participants still achieved significant HbA1c change using the interface as part of a comprehensive intervention; thus, given current VA infrastructure, telephone-based care strikes a reasonable balance between effectiveness, reach, and potential scalability. As technology evolves, and VA develops infrastructure to deliver alternatives to phone-based care delivery, ACDC's telemonitoring platform will evolve accordingly.
Minimizing treatment burden when intervening on complex diseases
Shippee et al 17 posit that for patients with complex conditions such as PPDM, engagement with health care is affected by the balance between their workload (ie, demands on their time and energy such as employment, self-care activities such as telemonitoring of SMBG) and their capacity to address their demands (ie, physical and mental ability, resources, and readiness). A patient's disease(s) can limit his capacity, and treatments to address disease(s) can increase his workload. 17, 18 Our data support the notion that for low-change participants, burden imposed by the intervention (ie, difficulty using the telemonitoring interface), combined with other demands in their lives, contributed to imbalance between their workload and their capacity to manage their diabetes; consequently, they were unable to engage with intervention components.
In contrast, feedback from high-change participants suggests that, while they may have also experienced increased burden as a result of intervention components, their capacity to manage this burden allowed them to engage with the intervention; intervention components then supported them in improving clinical outcomes, which further increased their capacity to self-manage. Additionally, our data suggest that some high-change participants were motivated to change prior to initiating the intervention. It is possible that for these participants, recognition of their disease severity and an increased readiness to change at baseline offset the effects of other factors in their lives that might have otherwise limited their engagement.
Ultimately, PPDM is a complex condition that requires comprehensive treatment. However, increasing the intensity of treatment, by definition, imposes additional burden on patients who may already have reduced capacity to manage their diabetes. 17, 18 Therefore, interventions targeting PPDM may be most successful if they include assessment of workload and capacity barriers prior to enrolling patients, and provision of capacity-bolstering support to offset treatment burden. Because social support and socioeconomic/cultural factors can also influence participants' capacity to engage 
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Patient perceptions of a comprehensive telemedicine intervention with interventions like ACDC, 12, 13, 16 future work should focus on further tailoring intervention content and delivery based on participants' level of social support, socioeconomic status, and cultural background.
Conclusion
We found that a comprehensive telehealth intervention that includes telemonitoring of SMBG, self-management support, and personalized medication management helped many participants with PPDM improve their diabetes control. However, intervention factors (eg, ease-of-use of telemonitoring technology) and individual factors (eg, the presence of competing life demands) affected some participants' engagement with the intervention. Differences in engagement may reflect differing capacity to manage treatment burden.
This approach is a promising model for addressing PPDM within VA and beyond. Within VA, the ability to leverage existing clinical infrastructure improves the feasibility of delivering this successful pilot intervention on a larger scale. Future work should focus on optimizing infrastructure to minimize the tension caused by using technology that promotes the scope of intervention delivery but may limit intervention engagement, and on developing alternate technology interfaces that are more satisfactory to participants (eg, mobile applications). Organizations implementing telemedicine interventions for PPDM should consider bundling strategies such as telemonitoring, regular self-management support, and frequent medication management, which comprehensively address factors that contribute to poor diabetes control. Additionally, our findings suggest that since patients with PPDM have a high clinical burden and are likely to have additional life demands, interventions targeted at this population may be more successful if they assess workload and capacity factors that may impede engagement. Patients who are identified as having a potential imbalance between workload and capacity may require more intensive support prior to, or during, interventions.
